Summary: The Board erred by failing to explain why it discarded material and unrebutted evidence that a reference constitutes prior art.

In CQV Co. Ltd. v. Merck Patent GmbH, the Federal Circuit addressed (1) the interaction of indemnification agreements with Article III standing ...

Yesterday, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision vacating the Patent Trial and ...

The Federal Circuit reinstated a challenge of a Merck KGaA unit’s pigment patent by South Korea-based CQV Co. on Monday, ...

Melasma is a common skin condition that causes patches of darker skin to form, often on the face. It tends to occur in areas with more sun exposure. Melasma is not harmful, but it may affect how a ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...